GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » FCF Margin %

TriSalus Life Sciences (TriSalus Life Sciences) FCF Margin % : -166.91% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TriSalus Life Sciences's Free Cash Flow for the three months ended in Dec. 2023 was $-9.55 Mil. TriSalus Life Sciences's Revenue for the three months ended in Dec. 2023 was $5.72 Mil. Therefore, TriSalus Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was -166.91%.

As of today, TriSalus Life Sciences's current FCF Yield % is -9.93%.

The historical rank and industry rank for TriSalus Life Sciences's FCF Margin % or its related term are showing as below:

TLSI' s FCF Margin % Range Over the Past 10 Years
Min: -285.14   Med: -276.41   Max: -158.79
Current: -158.79

During the past 3 years, the highest FCF Margin % of TriSalus Life Sciences was -158.79%. The lowest was -285.14%. And the median was -276.41%.

TLSI's FCF Margin % is ranked worse than
81.36% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: -7.29 vs TLSI: -158.79

TriSalus Life Sciences FCF Margin % Historical Data

The historical data trend for TriSalus Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences FCF Margin % Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
-285.14 -266.97 -276.41

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial - -354.69 -200.76 - -166.91

Competitive Comparison of TriSalus Life Sciences's FCF Margin %

For the Medical Devices subindustry, TriSalus Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's FCF Margin % falls into.


TriSalus Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TriSalus Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-51.166/18.511
=-276.41 %

TriSalus Life Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-9.549/5.721
=-166.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » FCF Margin %
Comparable Companies
INGN HYBT HYPR CLPT ELMD TELA MGRM AXDX APYX NSPR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
Website
https://trisaluslifesci.com
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10